

21 November 2018

ASX Limited
Level 6, Exchange Centre
20 Bridge Street
Sydney NSW 2000

**NOXOPHARM LIMITED (“NOX”)
Results of Annual General Meeting (“AGM”) of Members – 21 November 2018**

We advise that:

A. A summary of valid and eligible proxies received for the above meeting was as follows:

Resolution No and Type	Resolution Item	Proxy Results					
		For	Against	Abstain	Valid Open Proxy's Discretion ***	Invalid/ Excluded/ Open unusable **	Total *
1 Ordinary Non-Binding	Resolution 1 Adoption of the Remuneration Report	21,445,595	206,464	1,600	100,105	33,456,449	55,210,213
2 Ordinary	Resolution 2 Re-election of Director – Dr. Ian Dixon	53,177,208	-	1,932,900	100,105	-	55,210,213
3 Special	Resolution 3 Approval of 10% capacity to issue equity securities	54,896,054	77,554	136,500	100,105	-	55,210,213

* There were no invalid votes.

** There were no votes in the “votes excluded / no instruction” column in the table above where the nominee registered shareholder had not received instructions from the beneficial shareholder. The votes in this column are votes unable to be cast due to voting restrictions as outlined in the Notice of Meeting.

*** Of the ‘undirected votes’, 100,105 votes for Resolution 1, 2 and 3 were cast with the Chair as proxy, which as outlined in the Notice of Meeting would be voted FOR all resolutions.

B. The following resolutions were passed without resort to a poll at the AGM of NOX on 21 November 2018

Resolution 1:

Adoption of the Remuneration Report

The motion was *carried* as an ordinary non-binding resolution on a show of hands.

For the record, the show of hands and proxy positions were in excess of 75% in favour of this Resolution.

Resolution 2:

Re-election of Director – Dr. Ian Dixon

The motion was *carried* as an ordinary resolution on a show of hands.

Resolution 3:

Approval of 10% capacity to issue equity securities

The motion was *carried* as a special resolution on a show of hands.

For the record, the show of hands and proxy positions were in excess of 75% in favour of this Resolution.

Yours Sincerely



David Franks
Company Secretary
Noxopharm Limited

For further information, please contact:

David Franks
P: +61 2 9299 9690
E: david.franks@automicgroup.com.au

ABOUT NOXOPHARM GROUP

The Noxopharm Group includes Noxopharm Ltd, Nyrada Inc, and NoxAsia Ltd with offices in Sydney, New York and Hong Kong. The Group's drug pipeline contains 4 drug candidates: Veyonda[®], NYX-104, NYX-205, NYX-330. Veyonda[®] is being developed as an enhancer of radiotherapy across a range of cancers being treated with both standard external beam radiotherapy and intravenous radionuclide (¹⁷⁷lutetium-PSMA-617) therapy; NYX-104 is a neuroprotectant being developed to limit secondary brain damage (glutamate-induced excitotoxicity) following ischaemic stroke and concussion; NYX-205 is an anti-inflammatory being developed for the treatment of peripheral neuropathy associated with diabetes and chemotherapy; NYX-330 is a PCSK9 inhibitor being developed for the treatment of high blood LDL cholesterol levels that fail to respond adequately to statin therapy alone.